HLA-A and neoplasm: Furthermore, HLA‐A*02:01 carriers in CPC‐GENE did not have a higher tumor mutation burden compared to non‐carriers (Fig. 3B,C), which implies that HLA‐A*02:01 does not permit a large number of prostate cancer mutations to clonally expand through lack of immune recognition.